122709-21-1

Basic information

• Product Name: (S)-3-BOC-4-(METHOXYMETHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE
• Synonyms: (S)-3-BOC-4-(METHOXYMETHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE;tert-butyl 4-[Methoxy(Methyl)carbaMoyl]-2,2-diMethyl-1,3-oxazolidine-3-carboxylate;(S)-4-(Methoxy-Methyl-carbaMoyl)-2,2-diMethyl-oxazolidine-3-carboxylic acid tert-butyl ester;(S)-tert-Butyl 4-(Methoxy(Methyl)carbaMoyl)-2,2-diMethyloxazolidine-3-carboxylate;tert-Butyl (S)-4-(methoxy(methyl)carbamoyl)-2,2-dimethyloxazolidine-3-carboxylate;(4S)-3-Oxazolidinecarboxylic acid, 4-[(methoxymethylamino)carbonyl]-2,2-dimethyl-, 1,1-dimethylethyl ester
• CAS NO: 122709-21-1
• Molecular Formula: C₁₃H₂₄N₂O₅
• Molecular Weight: 288.34
• Mol File: 122709-21-1.mol

Chemical Properties

• Boiling Point: 349.7°Cat760mmHg
• Flash Point: 165.3°C
• Appearance: /
• Density: 1.118g/cm³
• Vapor Pressure: 4.63E-05mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-3-BOC-4-(METHOXYMETHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-BOC-4-(METHOXYMETHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE(122709-21-1)
• EPA Substance Registry System: (S)-3-BOC-4-(METHOXYMETHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE(122709-21-1)

Safety Data

• Hazardous Substances Data: 122709-21-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(S)-3-BOC-4-(METHOXYMETHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE is utilized as a reagent in organic synthesis for its ability to protect and modify functional groups in various chemical reactions. This capability is crucial for the selective synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-3-BOC-4-(METHOXYMETHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE is employed as a key intermediate in the synthesis of pharmaceutical compounds. Its unique structural features contribute to the development of new drugs and bioactive molecules, enhancing the discovery of potential therapeutic agents.
Used in Chemical Research:
(S)-3-BOC-4-(METHOXYMETHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE is also valuable in chemical research, where its specific properties are explored and harnessed to advance understanding in the field. Its role in protecting and modifying functional groups makes it instrumental in the synthesis of novel compounds for research purposes.
Used in Drug Discovery:
(S)-3-BOC-4-(METHOXYMETHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE's applications extend to drug discovery, where it aids in the creation of new pharmaceutical entities. Its unique structure and properties are leveraged to design and synthesize molecules with potential therapeutic effects, contributing to the advancement of medical treatments.

InChI:InChI=1/C13H24N2O5/c1-12(2,3)20-11(17)15-9(8-19-13(15,4)5)10(16)14(6)18-7/h9H,8H2,1-7H3/t9-/m0/s1

Upstream product

• 3262-72-4 (R)-N-tert-butoxycarbonyl serine 
• 59524-02-6 N-tert-butoxycarbonyl-L-serine benzyl ester 
• 122709-20-0 N-(tert-butoxycarbonyl)-L-serine N'-methoxy-N'-methylamide 
• 77-76-9 2,2-dimethoxy-propane 
• 67-64-1 acetone 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 25952-53-8 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride 
• 139009-66-8 (S)-3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 102308-32-7 (4S)-4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 488835-85-4 (4S)-4-(4-benzyloxyphenyl)-3-tert-butoxycarbonyl-2,2-dimethyloxazolidine 
• 149180-94-9 tert-butyl (4S,1'R)-4-(1'-benzyloxy-4'-oxobutyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 336625-39-9 tert-butyl (4S,1'R)-4-(1'-benzyloxy-4'-pentenyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 336625-45-7 (S)-4-((R)-1-Benzyloxy-4,5-dihydroxy-pentyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 336625-40-2 tert-butyl (4S,1'R)-4-(1'-benzyloxy-4'-hydroxyhexadecyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 336625-41-3 tert-butyl (4S,1'R)-4-(1'-benzyloxy-4'-oxohexadecyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 336625-42-4 (2S,3R)-3-benzyloxy-2-(tert-butoxycarbonylamino)-1-hydroxyoctadecane-6-one 
• 336625-43-5 (2S,3R)-2-(tert-butoxycarbonylamino)-1,3-dibenzyloxyoctadecane-6-one 
• 785828-28-6 tert-butyl (4S)-4-acetyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 162107-48-4 tert-butyl (R)-4-ethynyl-2,2-dimethyloxazolidine-3-carboxylate 
• 175696-50-1 tert-butyl [(2S,3S,4R)-1,3,4-trihydroxyoctadecan-2-yl]carbamate 

Relevant articles and documents

Direct Synthesis of N -Protected Serine- And Threonine-Derived Weinreb Amides via Diboronic Acid Anhydride-Catalyzed Dehydrative Amidation: Application to the Concise Synthesis of -Garner's Aldehyde

An efficient method for the direct synthesis of Weinreb amides derived from serine and threonine derivatives via diboronic acid anhydride-catalyzed hydroxy-directed amidation is described. This is the first successful example of the synthesis of serine- or threonine-derived Weinreb amides using catalytic dehydrative amidations. The methodology could be applied to the concise synthesis of Garner's aldehyde.

C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF

Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13- membered macrolides, pharmaceutical compositions comprising the 13-membered macrolides, and methods of treating infectious diseases, and in particular, disease resulting from Gram negative bacteria using the disclosed macrolides. Formula (I)

Novel Easily Recyclable Bifunctional Phosphonic Acid Carrying Tripeptides for the Stereoselective Michael Addition of Aldehydes with Nitroalkenes

A novel bifunctional organocatalyst library combining both aminocatalysis and phosphonic acid activation was used for the first time as an efficient tool for the stereoselective Michael addition of aldehydes with several aromatic nitroalkenes with good selectivities up to 95:5 dr and 93:7 er. Due to their high water solubility, the catalysts were easily recyclable and could be reused over several cycles without any significant loss of selectivity.

POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES

The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3

The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.

PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3

The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.

CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES

The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.

Studies toward asymmetric synthesis of leiodelide A

An enantioselective route for oxazoline 4, a key fragment toward the asymmetric synthesis of leiodelide A, is described. We synthesized northern subunit 6 through a Julia-Lythgoe olefination and subsequent Sharpless asymmetric dihydroxylation. Moreover, a highly diastereoselective method using well-established Evans' asymmetric aldol condensation was developed for preparation of southern fragment 5. The additional feature of this synthetic route is the formation of oxazoline 4 through DAST-promoted cyclization of the amidation product from subunits 5 and 6.

A reasonably stereospecific multistep conversion of Boc-protected α-amino acids to Phth-protected β3-amino acids

A method for the synthesis of β3-amino acids starting from α-amino acids is described. This conversion can be effected by an eight-step procedure which involves the transformation of the carboxylic group into an alkyne followed by a selenium-mediated conversion of the carbon-carbon triple bond to a Se-phenyl selenocarboxylate intermediate. The reactive Se-phenyl selenocarboxylate intermediates can be trapped with water, alcohols or the amine of an amino acid derivative to give β3-amino acids, β3-amino esters or mixed peptides, respectively. The whole transformations of the carboxylic group into an alkyne and of the alkyne group into β3-amino acids may not require purification of the intermediate products but a work-up and isolation procedure of crude materials.

SELECTIVE INHIBITORS FOR CYCLIN-DEPENDENT KINASES

This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.